Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
Method of stimulating an immune response (e.g., to treat cancer) include administering to a subject a composition including dendritic cells incubated with (i) oHSV-infected tumor cells or a composition derived therefrom, or (ii) tumor cells plus oHSV, as well as methods of preparing such compositions, are described.
1. A method of treating a subject for a brain tumor comprising:
administering to the subject a composition comprising mature dendritic cells produced by incubating a population of immature dendritic cells generated from a sample obtained from the subject or a closely matched donor, with:
(i) a brain tumor cell of the subject, infected with an effective amount of oncolytic herpes simplex virus (oHSV) G207 or G47Δ;
(ii) a composition derived from a brain tumor cell of the subject infected with an effective amount of oHSV G207 or G47Δ, wherein the composition is selected from the group consisting of supernatant, conditioned medium, eluate, and lysate;
(iii) A brain tumor cell of the subject and an effective amount of oHSV G207 or G47Δ; or
(iv) a composition derived from a brain tumor cell of the subject and an effective amount of oHSV G207 or G47Δ, wherein the composition is selected from the group consisting of supernatant, conditioned medium, eluate, and lysate;
to thereby produce mature dendritic cells;
to thereby treat the subject for the brain tumor.
2. The method of claim 1 , wherein the oHSV expresses an immunomodulatory transgene that encodes the immunomodulatory agent selected from the group consisting of Flt-3 ligand, CCL17, IL-18, HMGB1, and calreticulin.
3. The method of claim 1 , where in the population of immature dendritic cells comprises plasmacytoid dendritic cells and conventional dendritic cells.
4. The method of claim 1 , wherein the population of immature dendritic cells is generated from culturing bone marrow progenitor cells of the subject with Flt-3 ligand.